- Home
- ACRS vs KBON Comparison
ACRS vs KBON Comparison
Compare ACRS & KBON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ACRS | KBON |
|---|---|---|
| Founded | 2012 | 2025 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 311.0M | 344.2M |
| IPO Year | 2015 | N/A |
Fundamental Metrics
Financial Performance| Metric | ACRS | KBON |
|---|---|---|
| Price | $4.52 | $10.06 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $10.20 | N/A |
| AVG Volume (30 Days) | ★ 1.4M | 15.4K |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 69.01 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,683,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.24 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.20 | $10.04 |
| 52 Week High | $4.89 | $10.15 |
Technical Indicators
Market Signals| Indicator | ACRS | KBON |
|---|---|---|
| Relative Strength Index (RSI) | 61.08 | 48.42 |
| Support Level | $3.16 | $10.05 |
| Resistance Level | $4.56 | $10.09 |
| Average True Range (ATR) | 0.23 | 0.02 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 81.71 | 14.29 |
Price Performance
Historical ComparisonAbout ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
About KBON Karbon Capital Partners Corp. Class A Ordinary Shares
Karbon Capital Partners Corp is a blank check company.